[Alzheimer's Drug Discovery Foundation](https://www.alzdiscovery.org)

March 30, 2026 (Letter of Intent) | June 1, 2026 (Full proposal)

Up to $2,500,000 over 1–3 years; typical awards range from $500,000–$2,000,000.

Supports early-stage clinical trials and biomarker development for therapies targeting frontotemporal degeneration (FTD).

--- ## Description The Treat FTD Fund is a joint initiative of the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), designed to accelerate the development of new therapies for frontotemporal degeneration (FTD) disorders. The fund supports early and mid-stage clinical trials (phases 0, 1, or 2) of both novel and repurposed drug candidates or devices, with a focus on disease-modifying and symptomatic treatments. Projects should address unique FTD drug development challenges by leveraging advances in biological mechanisms, biomarker validation, and innovative clinical trial design. The program encourages milestone-driven studies with clear go/no-go criteria and supports both academic and biotech-led trials worldwide. --- ## Due Dates - **Letter of Intent:** March 30, 2026 - **Full Proposal:** June 1, 2026 --- ## Funding Amount - **Award Size:** Up to $2,500,000 total for 1–3 years, depending on stage and scope. - **Typical Range:** $500,000–$2,000,000. - **Funding Structure:** Milestone-based payments, with potential for follow-on funding. Co-funding from other sources is encouraged for larger studies. --- ## Eligibility - **Who Can Apply:** - Researchers and clinicians worldwide at academic medical centers, universities, or non-profits (industry partnerships encouraged). - Biotechnology companies (existing or new startups), provided there is a clear need for non-profit funding; funding is structured as mission-related investments with return on investment requirements tied to milestones. - **Project Scope:** - Clinical trials in FTD (phases 0, 1, or 2), including prevention trials in at-risk individuals. - Both genetic and sporadic forms of FTD disorders are eligible. - Both novel and repurposed drugs, as well as non-pharmacologic interventions (devices), are considered. - **Requirements:** - Drug candidates must have completed or be completing IND-enabling studies (or international equivalent). - Device trials require an approved IDE or equivalent. - Behavioral/social interventions and lifestyle modifications are not eligible. --- ## Application Process 1. **Letter of Intent (LOI):** - Submit via the [ADDF Funding Portal](https://addf.fluxx.io/). - Include project rationale, mechanism, drug description, supporting data, biomarkers, and trial design. - LOIs are reviewed for alignment with program priorities. 2. **Full Proposal:** - Invitation-only following LOI review. - Requires detailed clinical protocol, budget, biosketches, and (for biotech) a business packet. - Proposals reviewed by external scientific and business review boards. 3. **Required Materials:** - Project narrative (background, rationale, data, plan, methods, team, IP, other support, references). - Budget and justification (Excel template). - Compound report card, human subjects questionnaire, biosketches. - For biotech: business plan, financials, capitalization table, IP summary. - Optional: supplemental materials (protocols, letters of support, unpublished manuscripts). 4. **Registration:** - New applicants must register on the [ADDF Funding Portal](https://addf.fluxx.io/); allow 1–2 business days for approval. --- ## Additional Information - **Funding Priorities:** - Projects addressing mechanisms relevant to FTD and incorporating informative biomarkers. - Innovative, patient-centered clinical trial designs suitable for rare diseases. - Strong rationale and data supporting the intervention’s relevance to FTD. - Data sharing plans are required. - **Resources:** Leveraging patient registries, clinical networks, and existing resources is encouraged (see recommended resources in the program page). - **Milestone-Driven:** Awards are contingent on meeting agreed milestones and patient enrollment targets. --- ## External Links - [Treat FTD Fund Program Page](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/the-treat-ftd-fund) - [Application Instructions](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/the-treat-ftd-fund/the-treat-ftd-fund-application-instructions) - [ADDF Funding Portal](https://addf.fluxx.io/) - [Application and Funding Policies](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies) --- ## Contact Information | Purpose | Contact Name/Team | Email | |------------------------------------------|------------------------------------------|------------------------------------------| | Program-related inquiries (AFTD) | Nicole Bjorklund, PhD | [nbjorklund@theaftd.org](mailto:nbjorklund@theaftd.org?subject=Treat%20FTD%20RFP) | | Program-related inquiries (ADDF) | Aaron Burstein, PharmD | [aburstein@alzdiscovery.org](mailto:aburstein@alzdiscovery.org?subject=AFTD%20RFP) | | Application submission inquiries | Grants & Mission-Related Investments Team| [grants@alzdiscovery.org](mailto:grants@alzdiscovery.org?subject=FTD%20RFP) | | General foundation contact | Alzheimer's Drug Discovery Foundation | [info@alzdiscovery.org](mailto:info@alzdiscovery.org) | | | | [Contact Form](https://www.alzdiscovery.org/contact-us) | ---

Treat FTD Fund

Sign in to see full grant listing